Lacipil

Lacidipine, the active ingredient in Lacipil, is a calcium channel blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension, helping to reduce the risk of cardiovascular complications associated with sustained high blood pressure. The drug works by relaxing vascular smooth muscle, which decreases peripheral vascular resistance and improves blood flow.

GNH USA supplies Lacipil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation to support import and distribution in multiple jurisdictions.

Lacidipine is used primarily in the management of hypertension, a condition characterized by chronically elevated arterial pressure.

- Hypertension: reduces systolic and diastolic blood pressure by causing vasodilation of peripheral arteries.

Lacidipine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing. - Tachycardia: increased heart rate. - Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Angioedema: swelling of the face, lips, tongue, or throat. - Myocardial infarction: rare occurrence of heart attack. - Hepatic enzyme elevation: abnormal liver function tests. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy with Lacipil, clinicians should assess patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: check regularly to ensure therapeutic response and avoid excessive lowering. - Hepatic impairment: use cautiously; dose adjustment may be required. - Elderly patients: start at the lowest effective dose and monitor for orthostatic effects. - Concomitant antihypertensives: adjust doses to prevent additive hypotension. - CYP3A4 inhibitors: avoid strong inhibitors that may increase lacidipine levels. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lacidipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise lacidipine plasma concentrations. - Grapefruit juice: can increase systemic exposure and risk of hypotension.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., ACE inhibitors, beta‑blockers): may produce additive blood‑pressure lowering effects. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce lacidipine effectiveness. - Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): increased risk of statin‑related muscle toxicity. - Diuretics: may enhance orthostatic hypotension. - Nitrates: combined vasodilatory effect may cause excessive hypotension.